The Basel-based pharma company, Novartis, is to take a $235 million (SFr257.3 million) charge after stopping development of a treatment for bacterial infections.
This content was published on
1 minute
Novartis reported on Friday that its Aurograb medication had shown a lack of efficacy in mid-stage trials.
The charge, which reflects the full amount allocated to the project, will be taken in the company’s third-quarter results.
Novartis acquired Aurograb in 2006 when it bought NeuTec Pharma, a specialist in fighting hospital superbugs, for nearly $570 million.
Another compound acquired with NeuTec, Mycograb, continues in late-stage trials for the treatment of a life-threatening fungal infection.
Analysts at JP Morgan said in a note that the move would have “no significant impact on Novartis, although [it would be] a small negative for sentiment”.
You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis buys into eye care specialist
This content was published on
The drugmaker said in a statement on Tuesday that the price was $200 million less than previously announced, due to a dividend payment. The purchase is the first step in Novartis’ agreement to acquire a majority stake in American firm Alcon from Swiss food multinational Nestlé. The deal was announced in April. Novartis has the…
This content was published on
Like most of the drug industry, the company suffered from declining sales in key units, a lack of new products and pressure in the generic sector. Novartis’ record result was only achieved in part from the sales of the Gerber baby-food business and its medical nutrition division to another Swiss multinational, Nestlé. These two sales…
This content was published on
Novartis will cut another 2,500 jobs from its global total of 100,000, becoming the latest major drugmaker to undertake a deep restructuring. It is expected that 500 jobs will be lost in Switzerland, slightly more than four per cent of its local workforce. The Basel-based firm said on Thursday it would take a charge of…
You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.